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Familial hypobetalipoproteinemia (FHBL) is a co-dominant disorder either linked or not linked to apolipoprotein (apo) B gene.
Abetalipoproteinemia (ABL) is a recessive disorder due to mutations of microsomal triglyceride transfer protein (MTP) gene. We
investigated a patient with apparently recessive hypobetalipoproteinemia consistent with symptomatic heterozygous FHBL or a ‘‘mild’’ form
of ABL. The proband had fatty liver associated with LDL-cholesterol (LDL-C) and apo B levels < 5th percentile but no truncated apo B
forms detectable in plasma. MTP gene sequence revealed that he was a carrier of the I128T polymorphism and an unreported amino acid
substitution (V168I) unlikely to be the cause of hypobetalipoproteinemia. Apo B gene sequence showed that he was heterozygous for two
single base substitutions in exon 9 and 22 resulting in a nonsense (Q294X) and a missense (R1101H) mutation, respectively. Neither of his
parents carried the Q294X; his father and paternal grandmother carried the R1101H mutation. Analysis of polymorphic genetic markers
excluded non-paternity. In conclusion, the proband has a ‘‘de novo ‘‘mutation of apo B gene resulting in a short truncated apo B form (apo B-
6.46). Sporadic cases of FHBL with an apparently recessive transmission may be caused by ‘‘de novo’’ mutations of apo B gene.
D 2003 Elsevier B.V. All rights reserved.Keywords: Familial hypobetalipoproteinemia; ‘‘De novo’’ mutation; Truncated apolipoprotein B; Microsomal triglyceride transfer protein1. Introduction
Familial hypobetalipoproteinemia (FHBL) is a ‘‘relative-
ly’’ frequent genetic disorder characterized by plasma
levels of total cholesterol (TC), LDL-cholesterol (LDL-C)
and apolipoprotein B (apo B) below the 5th percentile of
the distribution in the general population. FHBL segregates
as an autosomal co-dominant trait [1]. The majority of
FHBL subjects are simple heterozygotes who are asymp-
tomatic or mildly symptomatic; a large proportion of them
have non-alcoholic fatty liver and a few may have diarrhea
and intestinal fat malabsorption [1–5]. FHBL appears to be
genetically heterogeneous; it may be linked or not linked to
the apo B gene [5]. The best characterized FHBL cases are0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.11.002
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gene which prevent the complete translation of apo B
mRNA leading to the production of truncated forms of
apo B. The size of truncated apo Bs, those identified so far,
varies from apo B-2 to apo B-89; truncated apo Bs shorter
than apo B-27/B-29 are not detectable in plasma as they
are not secreted as constituents of lipoproteins [1,5].
Recently a missense mutation in apo B (R463W) was
found to be the cause of FHBL in a large kindred [6].
The apo B harbouring R463W substitution is not secreted
as it is retained in the endoplasmic reticulum [6]. In other
FHBL families, where the apo B gene has been excluded,
linkage to a susceptibility locus on chromosome 3p21 has
been shown [7–9]. In some FHBL families, linkage to both
apo B and chromosome 3 locus (3p21) is absent [5]. In all
FHBL cases, regardless of the gene/locus involved, FHBL
lipoprotein phenotype co-segregates as a co-dominant trait
[5].
Abetalipoproteinemia (ABL) is an ‘‘exceedingly rare’’
disorder characterised by extremely low levels of apo B-
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is more severe than symptomatic heterozygous FHBL; ABL
patients usually have steatorrhea, failure to thrive and
variable neurological manifestations [1]. ABL is due to a
deficiency of the microsomal triglyceride transfer protein
(MTP), which is required for the assembly of apo B-
containing lipoproteins in the liver and intestine [10]. It is
conceivable that the severity of ABL phenotype is related to
the residual activity of MTP and the capacity to form
chylomicrons and VLDL. ABL has an autosomal recessive
transmission; obligate heterozygotes appear to have a nor-
mal lipid profile [1].
In this study we report a patient with primary hypobeta-
lipoproteinemia which appeared to be inherited as a reces-
sive trait suggesting the diagnosis of a ‘‘mild’’ ABL
phenotype. In fact the patient was found to have heterozy-
gous FHBL due to a ‘‘de novo’’ mutation in apo B gene,
predicted to produce a short truncated apo B (apo B-6.46)
not detectable in plasma.2. Subjects and methods
2.1. Clinical data
2.1.1. S.M. kindred
The proband S.M. (subject III-1 in Fig. 1) was a 12-year-
old boy born from non-consanguineous parents. He had a
normal growth. He was referred to the hospital at 11, for the
presence of hepatomegaly, a mild elevation of serum trans-
minases, and a mild steatorrhea (fecal fat = 10–15 g/24 h)
associated with low TC (102 mg/dl), triglycerides (27 mg/
dl) and apo B ( < 30 mg/dl). Liver ultrasound examination
revealed the presence of fatty liver. These clinical features
associated with low plasma lipids at that time suggested the
diagnosis of a ‘‘mild’’ form of ABL. Intestinal biopsy
revealed normal intestinal mucosa with no lipid infiltration
of the enterocytes. At the time of the observation (1998) the
proband was slightly overweight (BMI = 24.3 kg/m2) and
had mild hepatomegaly. Neurological examination, includ-
ing retinal fundus, was negative. Routine blood chemistryFig. 1. Pedigree of the S.M. family. The proband is indicated by an arrow.(with the exception of serum lipids and transaminases)
including HBsAg, HBcAb, HCV were within the normal
range or negative. Liver biopsy showed the presence of
steatosis in 40% of the hepatocytes (macro/micro fat drop-
lets), but no signs of inflammation, necrosis and iron
deposits.
Proband’s parents were healthy with a negative family
history for gastrointestinal and liver disorders or plasma
lipid abnormalities. Proband’s grandparents were alive and
in good health. The proband was treated with a low fat,
high carbohydrate diet supplemented with fat-soluble
vitamins.
Proband’s pedigree spans three generations and includes
seven living members (Fig. 1). All members of the kindred
available for the study were subjected to the evaluation of
the lipid profile and to the analysis of MTP and apo B genes
for the search of the sequence variants found in the
proband. Normal subjects were selected among laboratory
staff and medical students. All gave their informed consent
for the study. The study protocol was approved by the
institutional human investigation committee of each partic-
ipating institution.
2.1.2. Analysis of plasma lipids and lipoproteins
Blood was collected after overnight fasting, unless oth-
erwise specified. Plasma TC, TG, direct HDL-C, direct
LDL-C, apo A-I and apo B were measured enzymatically
using Roche Diagnostic GmbH reagents on a Hitachi 912
analyzer. Plasma lipoproteins were separated by continuous
density gradient ultracentrifugation [4].
2.1.3. Apolipoprotein analysis
Aliquots (15–50 Ag of protein) of lipoprotein fractions
were precipitated in 10% trichloroacetic acid and extracted
with ethanol–diethyl ether 3:2 (v/v). For the analysis of
apo B, the samples were separated by a linear (3.5/5–
10%) gradient sodium dodecyl sulfate (SDS)-PAGE [4].
For the analysis of the other apolipoproteins, the samples
were separated by a linear 5–20% gradient SDS-PAGE
[4].
2.1.4. Apo B immunoblot analysis
Aliquots of total plasma and plasma lipoproteins (50–60
Ag of protein) were delipidated and separated by linear 3.5/
5–10% or 5–20% gradient SDS-PAGE [4]. For immuno-
blotting, apolipoproteins were electro-transferred from the
gel to a Zeta Probe membrane (BioRad Laboratories,
Richmond, CA). The membranes were incubated with
anti-human apo B-100 sheep polyclonal antiserum, as
previously described [4].
2.1.5. Analysis of MTP gene
Genomic DNA was isolated from whole blood (Nucle-
oSpin Blood L, Macherey-Nagel, Duren, Germany). The
entire MTP coding region, including the 5V-flanking region,
all exons and at least 50 bp of intronic sequence at each
Table 1
Plasma lipids and lipoproteins in S.M. family
Subjects Age (years) TC TG LDL-C HDL-C Apo B Apo A-I Apo E genotype
Proband (III-1) 12 88 18 24 61 18 153 q3q3
Father (II-1) 47 170 94 97 59 62 143 q3q3
Mother (II-2) 40 227 78 148 67 84 194 q3q3
Paternal grandfather (I-1) 79 207 60 149 46 105 131 nd
Paternal grandmother (I-2) 78 274 73 150 110 91 263 nd
Maternal grandfather (I-3) 73 224 121 142 58 105 156 nd
Maternal grandmother (I-4) 69 222 67 139 69 96 165 nd
nd, not determined. Lipid and apoliprotein concentrations are expressed as mg/dl.
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chain reaction (PCR). The sequence of the primer pairs for
PCR amplification was kindly provided by Dr. J. Wetterau
(Bristol-Myers Squibb, Pharmaceutical Research Institute,
Princeton, USA). For all PCR amplifications, 0.1 Ag of
genomic DNA was added to 25-Al mixture containing 0.2
mmol/l of each deoxynucleoside triphosphate, 25 pmol of
each primer and 1.5-U Taq DNA polymerase (Expand
High Fidelity, Roche Diagnostics GmbH, Germany) in
PCR buffer (50 mmol/l KCl, 10 mmol/l Tris–HCl, pH 9,
and 1.5 mmol/l MgCl2). The amplification conditions were:
95 jC for 5 min followed by 30 cycles at 95 jC for 1 min/
51 jC for 1 min/68 jC for 1.5 min with a final elongation
at 72 jC for 5 min. The amplification products were
purified with High Pure PCR purification kit (Roche
Diagnostics), analysed by 2% agarose gel electrophoresis
and directly sequenced in two directions using the ampli-
fication primers, with BigDye Terminator Cycle sequenc-
ing Kit (PE, Applied Biosystems, Warrington, UK).
Sequences were detected on an Applied Biosystems 3100
DNA sequencer and results were analysed with ABI
PRISM SeqScape software (Applied Biosystems). Se-
quence variants found in automated sequencing were
always checked by using a second independent amplifica-Fig. 2. Density profile of plasma lipoproteins. Plasma lipoproteins were separated
VLDL+ IDL (fractions 1–3); LDL (fractions 4–9); HDL (fractions 10–18).tion of the affected DNA region and resequencing in both
directions or, when possible, by restriction enzyme diges-
tion (see below).
2.1.6. Analysis of apo B gene
Since no truncated apo B forms were detected in plasma
lipoproteins, the whole apo B gene was analysed as de-
scribed previously [4]. Sequence analysis was performed as
indicated above.
2.1.7. Screening of the MTP and apo B gene mutations
The screening of family members for the MTP and apo B
gene variants found in the proband (see results) was
performed by automated sequencing of PCR-amplified
exons harbouring these variants (see above). The screening
of the sequence variant (V168I) of MTP gene was per-
formed by PCR amplification of exon 5 followed by
digestion with the restriction enzyme BsaBI.
2.1.8. Complementary genetic analysis
Several polymorphisms of genes involved in lipid me-
tabolism [apo E (q2/q3/q4); CETP (B1/B2); FABP-2 (54 A/
T); apo A-V (-1131T/C); HL (-250G/A); ABCA1 (R219K)]
were examined [11–16]. In addition, multiplex reactionsby density gradient ultracentrifugation from the proband and his parents.
Table 2
Sequence variants of MTP gene in S.M. family
Sequence variant Proband Mother Father
Promoter  493 G/T G/T G/T G/T
Promoter  400 A/T A/T A/T A/T
Promoter  164 T/C T/C T/C T/C
Exon 3 c.383 T/C (I128T) T/C T/C T/C
Exon 5 c.502 G/A (V168I) G/A G/G G/A
Exon 7 c.891 C/G (H297Q) C/C C/C C/G
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previous reports [17,18].Fig. 3. Partial nucleotide sequence of exon 9 of apo B gene in proband
S.M.(panel A), his mother (panel B), and his father (panel C). The proband
was found to be heterozygous for a C!T transition (indicated by Y) that
converts the glutamine codon (CAG) at position 294 into a termination
codon (TAG) (Q294X). This mutation was not detected in proband’s
parents. Amino acids are indicated as single-letter code below the reference
nucleotide sequence. The arrow indicates the nucleotide involved in the
substitution.3. Results
3.1. S.M. kindred
Plasma levels of TC and LDL-C of proband S.M. (Table
1) were below the 5th percentile for age and sex (TC = 131.3
mg/dl; LDL-C = 63.8 mg/dl). The plasma levels of LDL-C
and apo B found in the proband were similar to those we
observed in FHBL heterozygotes for a short truncated form
of apo B (apo B-8.15) [4]. Plasma TC and LDL-C levels of
proband’ s father (Table 1) were below the mean values
found in age- and sex-matched controls (TC = 214.4F 39.2
mg/dl; LDL-C = 140.9F 33.5 mg/dl) but above the 5th
percentile of the general population. The plasma levels of
TC, LDL-C and apo B found in proband’s mother (Table 1)
were within the control range (TC = 205.5F 33.2 mg/dl;
LDL-C = 130.3F 32.1 mg/dl; apo B = 120.0F 23.8 mg/dl).
The density profile of plasma lipoproteins isolated from
the proband (Fig. 2) was characterised by a marked reduc-
tion of the LDL peak (fractions 4–9, d = 1.035–1.060 g/ml),
similar to that found in FHBL heterozygotes of our series
[2–4]. The LDL peak of proband’s father was intermediate
between that of the proband and that observed in proband’s
mother (Fig. 2).
The apo B present in each lipoprotein density fraction
was analysed by SDS-PAGE (5–10% and 5–20% poly-
acrylamide gradient gels). In the proband, the only detect-
able forms of apo B were apo B-48 and apo B-100 (data not
shown). Immunoblot of 5–10% and 5–20% polyacrylamide
gradient gels of lipoprotein fractions and lipoprotein infra-
nate failed to show truncated forms of apo B (data not
shown).
In view of these findings, we suspected that the proband
might have a ‘‘mild’’ form of ABL. For this reason we
sequenced the MTP gene first.
3.2. Analysis of MTP gene
The sequence of MTP gene (Table 2) showed that the
proband was heterozygous for two nucleotide substitutions
in the coding region that result in amino acid changes: (1)
c.383 T>C transition in exon 3 (I128T), a previously re-ported rare allele of a common polymorphism [19] and (2)
c.502 G>A transition in exon 5 (V168I) not reported
previously. He was also homozygous for the most frequent
polymorphic allele (c.891 C/C in exon 7) (H297) [19].
Proband’s father was heterozygous for I128T, V168I and
for the rare polymorphic allele in exon 7 (c.891 C/G,
H297Q) [19,20]. Proband’s mother was heterozygous only
for the I128T (Table 2). The sequence of the promoter
revealed that the proband was heterozygous for the fol-
lowing polymorphic sites:  493 G/T,  400 A/T,  164
T/C [19] (Table 2). The variant V168I is a conservative
amino acid substitution likely to have no effect on MTP
function. We screened a sample of 100 randomly selected
healthy subjects for this mutation and found four carriers.
This suggests that V168I is a rare polymorphism in our
population.
In view of these findings, we thought that the diagnosis
of a ‘‘mild ‘‘ form of ABL was unlikely. We considered the
option that the proband had a heterozygous FHBL (either
linked or not linked to the apo B gene) possibly inherited
from his father, whose plasma TC and LDL-C levels were in
the lower range of the normal values. We therefore decided
to sequence the whole apo B gene.
Table 3
Polymorphisms of genes involved in lipoprotein metabolism
Polymorphism Proband Mother Father
CETP B1/B2 B2/B2 B2/B2 B1/B2
FABP-2 54A/T A/A A/T A/T
Apo A-V-1131 T/C T/T T/T T/T
HL-250G/A G/G G/A G/G
ABCA1 R219K R/K R/K R/K
CETP, cholesteryl ester transfer protein; FABP-2, fatty acid binding
protein-2; HL, hepatic lipase; ABCA1, ATP-binding cassette transporter 1.
et Biophysica Acta 1688 (2004) 61–67 653.3. Analysis of apo B gene
The sequence of apo B gene revealed that the proband
was heterozygous for a C>T transition (c.1089 C>T) in exon
9, which causes the conversion of the glutamine codon
(CAG) into a termination codon (TAG) at position 294 of
the mature protein (Q294X) (Fig. 3, panel A). This is a
novel nonsense mutation predicted to generate a truncated
peptide of 293 amino acids (apo B-6.46). The proband was
also heterozygous for a G>A transition (c.3511 G>A) in
exon 22, which converts the arginine codon (CGT) into a
histidine codon (CAT) at position 1101 (R1101H) (Fig. 4,
panel A). This missense mutation has not been reported in
previous studies [21,22].
The sequence of apo B gene in proband’s parents
revealed that neither of them was heterozygous for the
nonsense mutation Q294X (Fig. 3). Proband’s father, how-
ever, was heterozygous for the R1101H substitution (Fig. 4).
This mutation was also found in proband’s paternal grand-
mother (data not shown). No sequence variants causing
amino acid substitutions were found in apo B gene of
proband’s mother.
S. Lancellotti et al. / BiochimicaFig. 4. Partial nucleotide sequence of exon 22 of apo B gene in proband
S.M. (panel A), his mother (panel B), and his father (panel C). The proband
and his father were found to be heterozygous for a G!A transition
(indicated by R) which converts the arginine codon (CGT) at position 1101
into a histidine codon (CAT) (R1101H). Amino acids are indicated as
single-letter code below the reference nucleotide sequence. The arrow
indicates the nucleotide involved in the substitution.3.4. Complementary genetic analysis
The proband and his parents were genotyped for several
polymorphisms of genes involved in lipoprotein metabo-
lism (Table 3). These results combined with those of MTP
gene (Table 2) were all consistent with paternity. Formal
paternity testing carried out with additional genetic
markers [17,18] indicated a likelihood of paternity of
99.99%.4. Discussion
In this study we report a patient with fatty liver disease
and mild steatorrhea associated with severe hypobetalipo-
proteinemia, as we observed in symptomatic FHBL hetero-
zygotes carrying short apo B truncations [4]. Since there
was no clear indication of a vertical transmission of hypo-
betalipoproteinemia in the kindred, we thought that the
proband might have: (i) recessive hypobetalipoproteinemia
suggestive of a ‘‘mild’’ form of ABL; (ii) heterozygous
FHBL (possibly transmitted by his father) with a different
phenotypic expression in the proband with respect to his
father; (iii) heterozygous FHBL due to a ‘‘de novo’’
mutation in apo B gene (or, for that matter, in other
candidate genes/loci).
The analysis of proband’s MTP gene revealed that he
was a carrier of a rare allele of a previously reported
polymorphism (I128T) [19] and a new rare polymorphism
in exon 5 (c. 502 G/A) predicted to result in a conservative
amino acid substitution (V168I). We considered also the
hypothesis that the c.502 G/A in exon 5 might result in a
splicing defect of MTP pre-mRNA; this mutation involves
the first nucleotide of an exon, which in most of the human
genes in a G [23]. A splicing defect might lead to a reduced
MTP content in liver and intestine and, as a result, an
impaired secretion of apo B-containing lipoproteins. Al-
though this is an attractive hypothesis, the effect of a
splicing defect would be undetectable (in terms of reduced
plasma LDL-C and apo B) in heterozygotes. Proband’s
father carried the same MTP variants as his son, despite
that he did not have the same lipoprotein phenotype, thus
indicating that these MTP variants were not the main cause
of the hypobetalipoproteinemia phenotype.
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have heterozygous FHBL due to a mutation in apo B gene,
causing a short truncated apo B. We assumed that the
mutation was transmitted by the father, whose plasma lipids
were close to the lower limit of the normal range. The
sequence of apo B gene revealed that the proband was
heterozygous for a novel nonsense mutation (Q294X),
predicted to generate a short truncated apo B (apo B-
6.46). Surprisingly neither of the proband’s parents carried
the same mutation. As non-paternity was excluded, we
concluded that the proband carried a ‘‘de novo’’ mutation
in apo B gene causing symptomatic heterozygous FHBL. To
the best of our knowledge, this is the first report of a ‘‘de
novo’’ mutation in the apo B gene causing FHBL. This
novel mutation involves a GC dinucleotide (GCAG>
GTAG), which is the third in the rank order of relative
mutability resulting in base-pair substitutions [24]. Whether
this mutation has occurred in the maternal or paternal germ
line cannot be established at present.
In view of the large size of apo B gene and the
heterogeneity of mutant alleles causing FHBL [1,5], one
would expect a large number of ‘‘de novo’’ mutations. It is
thus surprising that, up to now, only one ‘‘de novo’’
mutation has been discovered. Interestingly a similar situa-
tion seems to occur in familial hypercholesterolemia (FH),
where few ‘‘de novo’’ mutations of LDL-receptor gene have
been reported [17,18,25,26]. This unexpected situation is
probably related to the fact that the proportion of dominant
disorders due to ‘‘de novo’’ mutations is inversely related to
the biological fitness (i.e. the ability of an individual to
generate children who survive to adult life and reproduce)
[27]. Since FHBL and FH in the heterozygous state do not
impair biological fitness, one might expect the percentage of
‘‘de novo’’ mutations in these disorders to be very low.
Our proband was also a carrier of a previously unreport-
ed missense mutation of apo B (R1101H) which had been
inherited from his father. This mutation, as frequently
observed in many genetic disorders, involved a CG dinu-
cleotide (a hot spot for nucleotide substitutions) [24]. We do
not know whether R1101H is a rare neutral polymorphism
or a mutation which has measurable effects on apo B
metabolism. The fact that arginine and histidine are both
polar and positively charged amino acids and that the
R1101H substitution is outside the binding sites of apo B
for MTP and the LDL-receptor [28] would all support the
idea of a neutral rare polymorphism. One can argue,
however, that R1101H substitution might have some effect
on apo B metabolism, as the proband’s father (a R1101H
carrier) has borderline hypocholesterolemia. This hypothesis
seems unlikely since the paternal grandmother, a carrier of
the same mutation, has hypercholesterolemia and an LDL-C
level in the upper limits of the control values.
The nonsense mutation Q294X is the fourth apo B
mutation reported so far as the cause of very short truncated
apo Bs (with a size < 10% of apo B-100) [4,29–31], which
are not secreted into the plasma as lipoprotein constituentsor in lipid-free form. Apo B-6.46 is completely devoid of
the lipid associating domain present in the NH2-terminal
region of apo B-100 and of the multiple region involved in
MTP binding [28]. It is most likely therefore that apo B-6.46
does not associate with lipids and, for this reason, is rapidly
degraded intracellularly in both liver and intestine. Thus, in
our proband, the only apo B form synthesized in both
tissues is the one encoded by the normal allele. However,
the plasma level of apo B in our proband, as in other
heterozygous FHBL subjects with apo B truncations, is
much lower than the expected 50% value (i.e. 50% of the
level found in controls). This probably reflects a reduced
production rate of wild-type apo B (dominant negative
effect) [5].
In conclusion, we report the first ‘‘de novo’’ mutation of
apo B gene causing a short truncated apo B (apo B-6.46) in
a subject with symptomatic heterozygous FHBL. Although
a ‘‘de novo’’ mutation is probably a rare event, it is possible
that some sporadic cases of hypobetalipoproteinemia with
an apparent recessive transmission are in fact caused by ‘‘de
novo’’ mutations in apo B gene.Acknowledgements
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